335 results on '"Irvin William"'
Search Results
2. A video intervention to improve patient understanding of tumor genomic testing in patients with cancer.
3. Longitudinal patient-reported outcomes on genotype-guided irinotecan dosing: feasibility and clinical relevance.
4. Aspirin vs Placebo as Adjuvant Therapy for Breast Cancer
5. Stereotactic body radiation therapy (SBRT) in recurrent, persistent or oligometastatic gynecological cancers
6. A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer
7. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
8. Real-World Performance of a Comprehensive Genomic Profiling Test Optimized for Small Tumor Samples
9. FIGURE 1 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
10. Supplementary Figure S5 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
11. Supplementary Table S4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
12. Supplementary Data S2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
13. Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
14. Data from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
15. FIGURE 4 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
16. FIGURE 2 from Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit
17. Supplementary Figure S5 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
18. Supplementary Table S5 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
19. Supplementary Data S2 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
20. Data from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
21. Supplementary Methods S1 from Validation of Immunotherapy Response Score as predictive of pan-solid tumor anti-PD-1/PD-L1 benefit
22. Stereotactic body radiation therapy in the treatment of ovarian cancer
23. Supplemental Figure 1 from TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer
24. Supplementary Table 1 from Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
25. Data from Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019
26. Abstract PD8-06: Incidence of Acute and Persistent Clinically Meaningful Chemotherapy Induced Peripheral Neuropathy in Patients with Early-Stage Breast Cancer Receiving Taxane Therapy: SWOG S1714 (NCT# 03939481)
27. Development and validation of an integrative pan-solid tumor predictor of PD-1/PD-L1 blockade benefit
28. ANÁLISE DOS DESVIOS GEOMÉTRICOS E DESGASTE DA FERRAMENTA NO PROCESSO DE FURAÇÃO DE UM AÇO AISI 1045 COM BROCA HELICOIDAL DE AÇO RÁPIDO
29. Differences in clinician and patient assessment of baseline neuropathy in patients receiving taxane-based chemotherapy enrolled to SWOG S1714 (NCT# 03939481).
30. Comprehensive assessment of cytochromes P450 and transporter genetics with endoxifen concentration during tamoxifen treatment
31. Using the Rothman Index to Identify Oncology Patients at Risk for Postoperative Readmission [6J]
32. A randomized phase III, double-blinded, placebo-controlled trial of aspirin as adjuvant therapy for breast cancer (A011502): The Aspirin after Breast Cancer (ABC) Trial
33. Prediction of pan-solid tumor pembrolizumab benefit by integrating tumor mutation and gene expression profiling
34. Alliance A011801 (compassHER2 RD): postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer
35. Phase II Study of Bortezomib and Pegylated Liposomal Doxorubicin in the Treatment of Metastatic Breast Cancer
36. In vivo assessment of the metabolic activity of CYP2D6 diplotypes and alleles
37. Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760)
38. A phase I evaluation of the combination of vinflunine and erlotinib in patients with refractory solid tumors
39. Increasing the tamoxifen dose in CYP2D6 intermediate metabolizers increases toxicity.: 167E.
40. Cervical cancer and human papillomavirus in indigenous Guyanese women
41. A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.
42. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
43. Cervical adenocarcinoma in situ: the predictive value of conization margin status
44. Clinical Trials in the Elderly
45. Contributors
46. EPOXI (mission)
47. Comprehensive genomic profiling of 30,000 consecutive solid tumors
48. SWOG S1400F (NCT03373760): A phase II study of durvalumab plus tremelimumab for previously treated patients with acquired resistance to PD-1 checkpoint inhibitor therapy and stage IV squamous cell lung cancer (Lung-MAP Sub-study).
49. Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy
50. Institutional Profile: UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.